JP7875859B2 - 新規スピロピロリジン誘導抗ウイルス剤 - Google Patents
新規スピロピロリジン誘導抗ウイルス剤Info
- Publication number
- JP7875859B2 JP7875859B2 JP2023530325A JP2023530325A JP7875859B2 JP 7875859 B2 JP7875859 B2 JP 7875859B2 JP 2023530325 A JP2023530325 A JP 2023530325A JP 2023530325 A JP2023530325 A JP 2023530325A JP 7875859 B2 JP7875859 B2 JP 7875859B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- compound
- substituted
- optionally substituted
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117170P | 2020-11-23 | 2020-11-23 | |
| US63/117,170 | 2020-11-23 | ||
| US202163142663P | 2021-01-28 | 2021-01-28 | |
| US63/142,663 | 2021-01-28 | ||
| US17/479,244 US11384090B2 (en) | 2020-11-23 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
| US17/479,530 US11352363B1 (en) | 2020-11-23 | 2021-09-20 | Spiropyrrolidine derived antiviral agents |
| US17/479,244 | 2021-09-20 | ||
| US17/479,530 | 2021-09-20 | ||
| PCT/US2021/060247 WO2022109363A1 (en) | 2020-11-23 | 2021-11-22 | Novel spiropyrrolidine derived antiviral agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023551174A JP2023551174A (ja) | 2023-12-07 |
| JP2023551174A5 JP2023551174A5 (cg-RX-API-DMAC10.html) | 2024-11-20 |
| JP7875859B2 true JP7875859B2 (ja) | 2026-06-18 |
Family
ID=78725298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530325A Active JP7875859B2 (ja) | 2020-11-23 | 2021-11-22 | 新規スピロピロリジン誘導抗ウイルス剤 |
Country Status (13)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| US12643905B2 (en) | 2021-07-23 | 2026-06-02 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| CN117751124B (zh) * | 2021-12-17 | 2026-07-24 | 南京药石科技股份有限公司 | 螺环氧化吲哚类化合物及其用于制备抗病毒蛋白酶抑制剂药物的用途 |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| CA3254409A1 (en) * | 2022-03-18 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | PROCESSES FOR PREPARING SUBSTITUTED SPIROOXINDOLE DERIVATIVES |
| US12145942B2 (en) | 2022-04-05 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| AU2023303408A1 (en) | 2022-07-06 | 2024-12-19 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| CN116621918B (zh) * | 2022-07-20 | 2023-10-31 | 深圳信立泰药业股份有限公司 | 一种螺环化合物及其制备方法与应用 |
| CN115466189B (zh) * | 2022-09-19 | 2024-08-30 | 安徽普利药业有限公司 | 一种氨基酸及其衍生物的纯化方法 |
| IL320050A (en) * | 2022-10-06 | 2025-06-01 | Enanta Pharm Inc | Crystalline forms of SARS-anti-COV-2 compound |
| CN115894504A (zh) * | 2022-10-21 | 2023-04-04 | 深圳信立泰药业股份有限公司 | 一种冠状病毒3cl蛋白酶抑制剂及其用途 |
| EP4612156A1 (en) * | 2022-11-02 | 2025-09-10 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2024094152A1 (zh) * | 2022-11-03 | 2024-05-10 | 中国科学院上海药物研究所 | 一类螺环化合物、其制备方法及用途 |
| CN118852175A (zh) * | 2023-01-17 | 2024-10-29 | 深圳信立泰药业股份有限公司 | 一种螺环化合物晶型及其制备方法与应用 |
| CN119139307B (zh) * | 2023-12-29 | 2025-09-23 | 上海柯君医药科技有限公司 | 螺环类化合物在制备3CLpro蛋白酶抑制剂或药物中的用途 |
| CN119930495A (zh) * | 2025-01-22 | 2025-05-06 | 中国科学技术大学先进技术研究院 | 化合物及其制备方法 |
| CN120815076A (zh) * | 2025-07-28 | 2025-10-21 | 广州医科大学附属第一医院（广州呼吸中心） | Sal-0133在制备预防和/或治疗人鼻病毒感染的药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022054904A1 (ja) | 2020-09-11 | 2022-03-17 | 公立大学法人横浜市立大学 | 新型コロナウイルス感染症の予防又は治療用の食品組成物、医薬品組成物、医薬部外品組成物、化粧品組成物、及び雑貨 |
| JP2024500286A (ja) | 2020-11-23 | 2024-01-09 | エナンタ ファーマシューティカルズ インコーポレイテッド | 新規スピロピロリジン誘導抗ウイルス剤 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| US7504382B2 (en) | 2003-05-06 | 2009-03-17 | Cytovia, Inc. | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof |
| DE602004011047T2 (de) | 2003-05-13 | 2008-12-24 | Universität Zu Lübeck | Kristallstruktur von der humanen coronavirus 229e hauptproteinase und deren verwendung zur entwicklung von sars-inhibitoren |
| US20060014821A1 (en) | 2003-08-27 | 2006-01-19 | Agouron Pharmaceuticals, Inc. | Inhibitors of SARS 3C like protease |
| US7462594B2 (en) | 2003-12-31 | 2008-12-09 | Taigen Biotechnology Co., Ltd. | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases |
| WO2005113580A1 (en) | 2004-05-21 | 2005-12-01 | Pfizer Inc. | Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| WO2006061714A2 (en) | 2004-12-09 | 2006-06-15 | Pfizer Inc. | Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| MY160077A (en) * | 2011-01-21 | 2017-02-15 | Univ Sains Malaysia | Curcumin compounds and their preparations thereof |
| UY34094A (es) * | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| CA2850003C (en) | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
| CA2859915A1 (en) * | 2012-01-03 | 2013-07-11 | Ruey J. Yu | N-acylpeptide derivatives and their uses |
| CA2872147A1 (en) | 2012-05-02 | 2013-11-07 | Kansas State University Research Foundation | Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses |
| WO2017035409A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| US11013779B2 (en) * | 2016-06-20 | 2021-05-25 | Kansas State University Research Foundation | Small molecule therapeutic inhibitors against picornaviruses, caliciviruses, and coronaviruses |
| WO2018023054A1 (en) | 2016-07-28 | 2018-02-01 | Kansas State University Research Foundation | Protease transition state inhibitor prodrugs |
| UY37381A (es) | 2016-08-30 | 2018-03-23 | Glaxosmithkline Ip No 2 Ltd | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos |
-
2021
- 2021-11-22 WO PCT/US2021/060247 patent/WO2022109363A1/en not_active Ceased
- 2021-11-22 IL IL302991A patent/IL302991A/en unknown
- 2021-11-22 UY UY0001039529A patent/UY39529A/es not_active Application Discontinuation
- 2021-11-22 MX MX2023005984A patent/MX2023005984A/es unknown
- 2021-11-22 CA CA3173333A patent/CA3173333A1/en active Pending
- 2021-11-22 KR KR1020237020684A patent/KR20230124582A/ko active Pending
- 2021-11-22 AU AU2021381437A patent/AU2021381437C1/en active Active
- 2021-11-22 CN CN202111385187.8A patent/CN114524821B/zh active Active
- 2021-11-22 JP JP2023530325A patent/JP7875859B2/ja active Active
- 2021-11-22 EP EP21209522.8A patent/EP4001279A1/en active Pending
- 2021-11-23 TW TW110143587A patent/TW202237616A/zh unknown
-
2023
- 2023-05-22 CL CL2023001476A patent/CL2023001476A1/es unknown
- 2023-06-20 CO CONC2023/0008018A patent/CO2023008018A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022054904A1 (ja) | 2020-09-11 | 2022-03-17 | 公立大学法人横浜市立大学 | 新型コロナウイルス感染症の予防又は治療用の食品組成物、医薬品組成物、医薬部外品組成物、化粧品組成物、及び雑貨 |
| JP2024500286A (ja) | 2020-11-23 | 2024-01-09 | エナンタ ファーマシューティカルズ インコーポレイテッド | 新規スピロピロリジン誘導抗ウイルス剤 |
Non-Patent Citations (1)
| Title |
|---|
| ChemRxiv ，2020，2020 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021381437A9 (en) | 2024-10-10 |
| IL302991A (en) | 2023-07-01 |
| CN114524821B (zh) | 2026-01-02 |
| CA3173333A1 (en) | 2022-05-27 |
| TW202237616A (zh) | 2022-10-01 |
| CN114524821A (zh) | 2022-05-24 |
| JP2023551174A (ja) | 2023-12-07 |
| EP4001279A1 (en) | 2022-05-25 |
| CO2023008018A2 (es) | 2023-07-10 |
| AU2021381437B2 (en) | 2025-12-18 |
| KR20230124582A (ko) | 2023-08-25 |
| UY39529A (es) | 2022-06-30 |
| MX2023005984A (es) | 2023-08-17 |
| CL2023001476A1 (es) | 2023-12-11 |
| AU2021381437C1 (en) | 2026-04-02 |
| WO2022109363A1 (en) | 2022-05-27 |
| AU2021381437A1 (en) | 2023-06-22 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241112 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251014 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260508 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260608 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7875859 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |